Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Polyclonal B cell response wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Adoptive cell transfer wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Management of multiple sclerosis wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
New anti-CD24 monoclonal antibody-based therapy in active IBD (Ulcerative colitis and Crohns' disease) patients Inventors Prof. Nadir Arber, Specialist in Gastroenterology, Head of the Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center Background, highlights & our innovation: The inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, are chronic inflammatory disorders caused by dysregulated immune responses in genetically predisposed individuals. IBD is characterized by oxidative stress, infiltration of inflammatory cells and up-regulation of pro-inflammatory cytokines. Patients with long-standing IBD have an increased risk of developing colorectal cancer (CRC) which is a major cause of morbidity and mortality in the Western world. Many of the molecular alterations responsible for CRC, namely chromosomal instability, hypermutability in oncogenes and tumor suppressor genes, play also a role in colitis-associated colon carcinogenesis. CD24, a cell surface molecule, is a heavily glycosilated phosphatidylinositol-anchored mucin-like protein that was shown to be a potential oncogene in the multistep process of CRC carcinogenesis (Sagiv et al., 2006). CD24 is overexpressed in a variety of malignancies including B-cell lymphomas, gliomas, small-cell and non-small cell lung, hepatocellular, renal cell, nasopharyngeal, bladder, uterine, epithelial ovarian, breast, prostate, and pancreatic carcinomas. Previous studies in our laboratory have shown an increased expression of CD24 in colorectal adenomas and adenocarcinomas as compared to normal adjacent tissue. Moreover, we found that treatment of human CRC (HT29) cells with antiCD24 monoclonal antibodies (mAbs) reduced their viability and inhibited cell growth in a timeand dose-dependent manner (Sagiv et al., 2008). This data suggests that CD24 is an important target for chemoprevention and anti-tumor therapy. We have evaluated the role of CD24 in IBD development in animal models of experimental colitis induced by either DSS or TNBS in mice. Our data shows that treatment of DSS or TNBS-induced colitis in mice, with anti-CD24 mAbs, induce a dose-dependent reduction in the inflammation scores both at the macro- and microscopic levels (unpublished data). These results suggest that CD24 is apparently involved in the development of IBD in mice. Therefore, anti-CD24 antibody therapy is potentially useful for the treatment of colitis in mice and may be a novel treatment for IBD in humans. Potential applications: Based on the fact that CD24 is overexpressed in CRC and plays a role in the multistep process of CRC carcinogenesis we hypothesize that CD24 may play a role in the pathogenesis of IBD and serve as a target for therapy of IBD using anti-CD24 mAb.